Is the place of nitrates preserved in the treatment of heart failure?

I.V. Shklianka, O.A. Yepanchintseva, O.J. Zharinov

References

1. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, et al. et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. New Engl J Med. 1986;314:1547-1552. doi: 10.1056/NEJM198606123142404
2. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Bruce W Dunkman, Loeb H, Wong M, Bhat G, Goldman S et al. A comparison of enalapril with hydralazine–isosorbide dinitrate in the treatment of chronic congestive heart failure. New Engl J Med. 1991;325:303-310. doi: 10.1056/NEJM199108013250502
3. Elliot H. Current Issues in Cardiovascular Therapy. Martin Dunitz, Glasgow, UK, 1997.
4. Gupta D, Georgiopoulou VV, Kalogeropoulos AP. et al. Nitrate therapy for heart failure: benefits and strategies to overcome tolerance. JACC: Heart Failure. 2013;1 (Iss. 3):183-191.
5. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41 (3):407-477. doi: 10.1093/eurheartj/ehz425
6. Montalescot G, Sechtem U, Achenbach S. et al. 2013 ESC guidelines on the management of stable coronary artery disease. The task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34 (38):2949-3003.
7. Mullens W, Abrahams Z, Francis GS. et al. Usefulness of isosorbide dinitrate and hydralazine as add on therapy in patients discharged for advanced decompensated heart failure. Am J Cardiol. 2009;103:1113-1119.
8. Ponikowski P, Voors AA, Anker SD. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-2200. doi: 10.1093/eurheartj/ehw128
9. Redfield MM, Anstrom KJ, Levine JA. et al. NHLBI Heart Failure Clinical Research Network. Isosorbide mononitrate in heart failure with preserved ejection fraction. New Engl J Med. 2015;373 (24):2314-2324. 
10. Tsujimoto Tetsuro, Kajio Hiroshi. Use of nitrates and risk of cardiovascular events in patients with heart failure with preserved ejection fraction. Mayo Clinic Proceedings. 2019;94:1125-1127. doi: 10.1016/j.mayocp.2018.11.032
11. Vizzardi E, Bonadei I, Riccardo R. et al. When should we use nitrates in congestive heart failure? Cardiovascular Therapeutics. 2013;31:27-31. doi: 10.1111/j.1755-5922.2012.00311
12. Yancy CW, Jessup M, Bozkurt B. et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137-e161. doi: 10.1161/CIR.0000000000000509

[PDF] [Contents]